文献速递肝病消化道肿瘤与早癌

嵌合抗原受体(CAR)T细胞疗法:改造免疫细胞以治疗肝病

Chimeric antigen receptor (CAR) T-cell therapy: Engineering immune cells to treat liver diseases.
PubMed 文献 · J Hepatol · 2025-06-20

本综述概述CAR技术的基本原理与关键成就,聚焦其在肝炎病毒感染、自身免疫性肝病和肝胆肿瘤中的应用,并讨论靶向衰老细胞的senolytic疗法、肝纤维化及诱导肝移植免疫耐受的调节性CAR T细胞,最后探讨提高特异性、疗效与安全性的研究方向。

要点

  • CAR T细胞通过抗体来源的识别域绕开HLA限制,靶向表面抗原。
  • CAR T细胞疗法已改变血液系统B细胞恶性肿瘤的治疗格局。
  • 综述聚焦肝病应用:肝炎病毒感染、自身免疫性肝病、肝胆肿瘤。

核心结论

  • CAR T细胞疗法在血液系统B细胞恶性肿瘤中已带来变革,近期研究显示其对实体瘤具有治疗潜力。
  • 本综述聚焦CAR技术在肝炎病毒感染、自身免疫性肝病和肝胆肿瘤中的应用,并讨论靶向衰老细胞与肝纤维化的senolytic疗法及诱导肝移植免疫耐受的调节性CAR T细胞。
  • 未来研究旨在提高CAR类「活体药物」的特异性、疗效和安全性,以实现肝病的靶向、持久和个体化治疗。

研究设计与样本

  • 综述文章,概述CAR技术的基本原理与关键成就,聚焦肝脏疾病中的应用。

主要发现

  • 内源性T细胞通过人类白细胞抗原(HLA)/肽复合物识别抗原,HLA多态性对广泛适用的过继T细胞疗法构成主要挑战。
  • 工程化T细胞通过合成嵌合抗原受体(CAR)绕开HLA限制,该受体将抗体来源的识别域与细胞内信号基序融合,独立于HLA靶向表面抗原。
  • CAR T细胞疗法已改变血液系统B细胞恶性肿瘤的治疗格局,近期研究显示其对实体瘤具有治疗潜力。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Endogenous T cells recognise antigens through human leukocyte antigen (HLA)/peptide complexes. However, HLA polymorphism poses a major challenge to the development of broadly applicable adoptive T-cell therapies. Engineered T cells can circumvent this barrier by targeting surface antigens independently from HLA through a synthetic chimeric antigen receptor (CAR) with an antibody-derived recognition domain fused to intracellular signalling motifs. CAR T-cell therapies have transformed the treatment of B-cell malignancies in haematology, and recent studies demonstrate therapeutic potential against solid tumours. In this review, we provide an overview of the fundamental principles and key achievements of CAR technology, with a focus on its applications in hepatic viral infections, autoimmune liver diseases, and hepatobiliary tumours. We also highlight emerging senolytic therapies targeting senescent cells and hepatic fibrosis, as well as regulatory CAR T cells designed to induce liver-specific immune tolerance in transplantation. Finally, we discuss ongoing and future research aimed at improving the specificity, efficacy, and safety of CAR-based therapies as "living drugs" for targeted, durable, and personalised treatment of liver diseases.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Jaeckel E, Friedman SL, Hudecek M, et al. Chimeric antigen receptor (CAR) T-cell therapy: Engineering immune cells to treat liver diseases. J Hepatol. 2025. PMID: 40545042. doi:10.1016/j.jhep.2025.06.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。